Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 10:25 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 136 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Namenda/Memantine Clear all
Completed Not applicable Interventional Results available

Memantine for Treatment of Cognitive Impairment in Patients With Parkinson's Disease and Dementia

NCT00294554
View directory record Official record
Conditions
Parkinson's Disease, Cognitive Impairment, Dementia
Interventions
Memantine, Placebo Oral Tablet
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
50 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 12, 2017 · Synced Oct 30, 2026, 10:25 AM EDT
Completed Phase 2Phase 3 Interventional

Trial of Memantine for Cognitive Impairment in Multiple Sclerosis

NCT00300716
View directory record Official record
Conditions
Multiple Sclerosis, Cognition Disorders
Interventions
Memantine
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 65 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
4
States / cities
Los Angeles, California • Portland, Oregon • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2019 · Synced Oct 30, 2026, 10:25 AM EDT
Active, not recruiting Phase 2 Interventional

Evaluating the Neurophysiologic and Clinical Effects of Single Dose Drug Challenge

NCT05418049
View directory record Official record
Conditions
Fragile X Syndrome
Interventions
Baclofen, Memantine, Roflumilast, Placebo
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
18 Years to 45 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Oct 30, 2026, 10:25 AM EDT
Completed Phase 3 Interventional Results available

Memantine Hydrochloride and Whole-Brain Radiotherapy With or Without Hippocampal Avoidance in Reducing Neurocognitive Decline in Patients With Brain Metastases

NCT02360215
View directory record Official record
Conditions
Cognitive Impairment, Metastatic Malignant Neoplasm in the Brain, Solid Neoplasm
Interventions
Whole brain radiation therapy with hippocampal avoidance, Memantine, Whole brain radiation therapy
Radiation · Drug
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
518 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
212
States / cities
Tuscaloosa, Alabama • Gilbert, Arizona • Tucson, Arizona + 172 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 30, 2026, 10:25 AM EDT
Completed Phase 4 Interventional

Memantine for Corticosteroid-Induced Mood and Declarative Memory Changes

NCT00280774
View directory record Official record
Conditions
Physiological Effects of Drugs
Interventions
Memantine
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 25, 2008 · Synced Oct 30, 2026, 10:25 AM EDT
Completed Not applicable Interventional Results available

Does Memantine Improve Verbal Memory Task Performance in Subjects With Partial Epilepsy and Memory Dysfunction?

NCT01054599
View directory record Official record
Conditions
Epilepsy
Interventions
Memantine, Sugar Pill
Drug · Other
Lead sponsor
American Academy of Neurology
Other
Eligibility
18 Years to 65 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
3
States / cities
Atlanta, Georgia • Boston, Massachusetts • Newton, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 11, 2017 · Synced Oct 30, 2026, 10:25 AM EDT
Completed Phase 4 Interventional Results available

A Study of Memantine Hydrochloride (Namenda®) for Cognitive and Behavioral Impairment in Adults With Autism Spectrum Disorders

NCT01333865
View directory record Official record
Conditions
Autism Spectrum Disorders
Interventions
Memantine
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 50 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 1, 2024 · Synced Oct 30, 2026, 10:25 AM EDT
Completed Phase 4 Interventional

An Open-Label Trial of Memantine for Cognitive Impairment in Patients With Post-Traumatic Stress Disorder

NCT02258828
View directory record Official record
Conditions
PTSD
Interventions
Memantine, Placebo
Drug
Lead sponsor
Sriram Ramaswamy
Federal
Eligibility
19 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated May 22, 2020 · Synced Oct 30, 2026, 10:25 AM EDT
Completed Phase 3 Interventional Results available

A Study of the Safety and Efficacy of Memantine in Moderate to Severe Alzheimer's Disease

NCT00322153
View directory record Official record
Conditions
Dementia of the Alzheimer's Type
Interventions
memantine ER, Placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
50 Years and older
Enrollment
677 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
38
States / cities
Phoenix, Arizona • Costa Mesa, California • Fresno, California + 34 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2010 · Synced Oct 30, 2026, 10:25 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Biomarker Strategies for Medication-Enhanced Cognitive Training in Schizophrenia

NCT01555697
View directory record Official record
Conditions
Schizophrenia
Interventions
Memantine, Placebo
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 55 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Oct 4, 2022 · Synced Oct 30, 2026, 10:25 AM EDT
Completed Phase 4 Interventional Results available

Open-Label Pilot Study of Namenda in Adult Subjects With ADHD and ADHD NOS

NCT00586573
View directory record Official record
Conditions
ADHD
Interventions
memantine hydrochloride
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 55 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 7, 2012 · Synced Oct 30, 2026, 10:25 AM EDT
Completed Phase 4 Interventional Results available

Brain Aging and Treatment Response in Geriatric Depression

NCT01902004
View directory record Official record
Conditions
Mild Cognitive Impairment (MCI), Depression
Interventions
Escitalopram, Memantine, Placebo
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
60 Years and older
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 15, 2019 · Synced Oct 30, 2026, 10:25 AM EDT
Completed Phase 4 Interventional Results available

Study of Memantine to Treat Huntington's Disease

NCT00652457
View directory record Official record
Conditions
Huntington's Disease
Interventions
Memantine
Drug
Lead sponsor
Jody Corey-Bloom, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
3
States / cities
La Jolla, California • Kansas City, Kansas • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Oct 30, 2026, 10:25 AM EDT
Terminated Phase 3 Interventional

Preventing pAIn With NMDA Antagonists - Steroids in Thoracoscopic lObectomy Procedures (PAIN-STOP) Pilot Trial

NCT02950233
View directory record Official record
Conditions
Pain, Postoperative
Interventions
NMDA active, Steroid active, NMDA placebo, Steroid placebo
Drug
Lead sponsor
Population Health Research Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 18, 2020 · Synced Oct 30, 2026, 10:25 AM EDT
Terminated Not applicable Interventional Results available

Memantine in Adult Autism Spectrum Disorder

NCT01078844
View directory record Official record
Conditions
Autism, Asperger's Disorder, Pervasive Developmental Disorder NOS
Interventions
memantine, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 85 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 26, 2017 · Synced Oct 30, 2026, 10:25 AM EDT
Terminated Phase 2 Interventional Results available

Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)

NCT01592773
View directory record Official record
Conditions
Autism Spectrum Disorder (ASD), Autism, Autistic Disorder, Asperger's Disorder, Asperger's, Pediatric Autism, Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Interventions
Memantine Hydrochloride (HCl)
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
6 Years to 12 Years
Enrollment
747 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
68
States / cities
Dothan, Alabama • Phoenix, Arizona • Tucson, Arizona + 62 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2015 · Synced Oct 30, 2026, 10:25 AM EDT
Recruiting Phase 2Phase 3 Interventional

A Prospective Study of Memantine in Patients With Cirrhosis and Liver Cancer

NCT06007846
View directory record Official record
Conditions
Hepatocellular Carcinoma, Cirrhosis
Interventions
Namenda
Drug
Lead sponsor
Inova Health Care Services
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
2
States / cities
Fairfax, Virginia • Falls Church, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 30, 2026, 10:25 AM EDT
Completed Phase 2 Interventional

An Evaluation of the Safety and Efficacy of Memantine in Patients With Acute Mania Associated With Bipolar I Disorder

NCT00106405
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Memantine HCl
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 65 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
6
States / cities
National City, California • Baltimore, Maryland • Saint Charles, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2012 · Synced Oct 30, 2026, 10:25 AM EDT
Terminated Phase 3 Interventional Results available

Comparing Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery in Patients With Cancer That Has Spread to the Brain and Come Back in Other Areas of the Brain After Earlier Stereotactic Radiosurgery

NCT04588246
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Lung Small Cell Carcinoma, Metastatic Malignant Breast Neoplasm, Metastatic Malignant Digestive System Neoplasm, Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Metastatic Renal Cell Carcinoma, Recurrent Brain Neoplasm, Stage IV Lung Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
Interventions
Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Memantine, Quality-of-Life Assessment, Questionnaire Administration, Stereotactic Radiosurgery, Whole-Brain Radiotherapy
Procedure · Drug · Other + 1 more
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
79
States / cities
Tucson, Arizona • Corona, California • Duarte, California + 63 more
Source: ClinicalTrials.gov public record
Updated May 20, 2026 · Synced Oct 30, 2026, 10:25 AM EDT
Active, not recruiting Phase 3 Interventional

Testing if High Dose Radiation Only to the Sites of Brain Cancer Compared to Whole Brain Radiation That Avoids the Hippocampus is Better at Preventing Loss of Memory and Thinking Ability

NCT04804644
View directory record Official record
Conditions
Metastatic Lung Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Brain, Recurrent Lung Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Interventions
Biospecimen Collection, Magnetic Resonance Imaging, Memantine Hydrochloride, Neurocognitive Assessment, Stereotactic Radiosurgery, Survey Administration, Whole-Brain Radiotherapy
Procedure · Drug · Other + 1 more
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2031
U.S. locations
227
States / cities
Phoenix, Arizona • Anaheim, California • Bellflower, California + 172 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 30, 2026, 10:25 AM EDT
Terminated Phase 4 Interventional Results available

Effect of Namenda on Short Term Memory and Attention in Patients With Mild to Moderate Traumatic Brain Injury

NCT00462228
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
Memantine, Placebo
Drug
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years to 50 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 23, 2017 · Synced Oct 30, 2026, 10:25 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

A Pilot Clinical Trial Of Memantine for Essential Tremor

NCT00439699
View directory record Official record
Conditions
Essential Tremor
Interventions
Memantine
Drug
Lead sponsor
VA Greater Los Angeles Healthcare System
Federal
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 22, 2012 · Synced Oct 30, 2026, 10:25 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Behavioral Treatment and Memantine in Body Focused Repetitive Behaviors

NCT05796752
View directory record Official record
Conditions
Skin-Picking, Trichotillomania (Hair-Pulling Disorder)
Interventions
Memantine, ComB Behavioral Therapy
Drug · Behavioral
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 30, 2026, 10:25 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Memantine Treatment in Fragile X-Associated Tremor/Ataxia Syndrome

NCT00584948
View directory record Official record
Conditions
Fragile X-Associated Tremor/Ataxia Syndrome, Fragile X Premutation Carriers
Interventions
Memantine, Placebo
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
30 Years to 80 Years
Enrollment
94 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2012
U.S. locations
2
States / cities
Sacramento, California • Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 30, 2026, 10:25 AM EDT